[8-K] Allarity Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

On 15 Jul 2025 Allarity Therapeutics, Inc. (NASDAQ: ALLR) filed a Form 8-K under Item 8.01 to disclose the execution of a new commercial agreement with an undisclosed EU-based biotechnology company. The filing states only that the agreement was announced via a press release furnished as Exhibit 99.1, which is incorporated by reference.

No financial terms, partner identity, milestones, or projected revenue were provided in the 8-K, and the company did not report any changes to financial statements, guidance, or capital structure. Other 8-K items were not triggered. Investors must review Exhibit 99.1 for substantive economic details before assessing materiality.

Positive

• Execution of a new commercial agreement suggests external validation of ALLR's technology and may create future revenue opportunities.

Negative

• No financial terms or partner identity disclosed, limiting investors’ ability to gauge materiality.
• Absent quantitative guidance leaves uncertainty about potential earnings impact.

Insights

Financial Analyst

TL;DR: ALLR discloses a new EU commercial deal; positive but materiality unknown without terms.

The 8-K signals potential pipeline or market-access progress because a fresh commercial partnership could open revenue channels or validate technology. However, neither counter-party nor economics are revealed, preventing any discounted-cash-flow impact assessment. Until Exhibit 99.1 or future filings quantify payments, milestones, or geographic scope, the market reaction should remain muted. I therefore classify the disclosure as neutral in valuation terms, albeit directionally positive for strategic momentum.

false 0001860657 0001860657 2025-07-15 2025-07-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 15, 2025

ALLARITY THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41160		87-2147982
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

123 E Tarpon Ave,

Tarpon Springs, FL 34689

(Address of principal executive offices)

(401) 426-4664

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ALLR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On July 15, 2025, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing the signing of a new commercial agreement with a non-disclosed EU-based biotechnology company. The Company’s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release, dated July 15, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Allarity Therapeutics, Inc.
Date: July 16, 2025	By:	/s/ Thomas H. Jensen
		Thomas H. Jensen
		Chief Executive Officer

2

FAQ

What did Allarity Therapeutics (ALLR) disclose in its July 15, 2025 8-K?

The company announced it has signed a new commercial agreement with an undisclosed EU-based biotechnology firm.

Who is Allarity’s partner in the new commercial agreement?

The 8-K does not identify the partner; it is described only as an EU-based biotechnology company.

Are financial terms or revenue projections included in the filing?

No. The 8-K contains no financial metrics, milestones, or guidance related to the agreement.

Where can investors find additional details about the deal?

Further information is expected in Exhibit 99.1, the press release dated July 15, 2025, referenced in the filing.

Does the 8-K affect Allarity’s current financial statements or guidance?

No changes to financial statements or guidance were reported in this filing.